Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193200 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Neurological Effects of EryDex on Subjects With A-T
A Phase 3 study, sponsored by Quince Therapeutics S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT06193200: Completed Phase 3 study, sponsored by Quince Therapeutics S.p.A..
NCT06193200 is a Phase 3 study that has completed, run by Quince Therapeutics S.p.A.. The registered enrollment target is 105 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06193200, a Phase 3 study, has completed, sponsored by Quince Therapeutics S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Primary Outcome
Change of the RmICARS from baseline to Visit 9 compared to placebo (6 to 9 years old). RmICARS (International Cooperative Ataxia Rating Scale): Score (range 0-29); higher score indicates worse disease.
Interventions
- OTHER Placebo
- DRUG Dexamethasone sodium phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 3 |
What the finished NCT06193200 record still lists
NCT06193200 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06193200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06193200 about?
NCT06193200 is a clinical study titled "Evaluate the Neurological Effects of EryDex on Subjects With A-T". This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological...
What is the current status of trial NCT06193200?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2024-06-24. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT06193200?
The interventions under investigation include: Placebo (OTHER), Dexamethasone sodium phosphate (DRUG).
Who is sponsoring clinical trial NCT06193200?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06193200's enrollment target sits among peer trials
105 1670th of 2000 higher than 330 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI